The Role of Lebrikizumab in the Treatment of Atopic Dermatitis in the Adult Population
Largo Medical Center
IL-13, atopic dermatitis, biologics, eczema, immunosuppressants, management
Dermatology | Skin and Connective Tissue Diseases
Although there are many atopic dermatitis (AD) treatments, finding a long-term medication with minimal side effects can be difficult. This review characterizes lebrikizumab as AD treatment in adults. A literature search was conducted to examine lebrikizumab's role in treating moderate to severe AD. In a phase III trial, 74% of adults with AD treated with lebrikizumab 250 mg every 4 weeks achieved an Investigator Global Assessment of 0/1, 79% achieved Eczema Area and Severity Index 75 and 79% experienced improvements in pruritus numeric rating scale scores relative to placebo. Common adverse effects in the ADvocate1 and ADvocate2 trials were conjunctivitis (7 and 8%, respectively), nasopharyngitis (4 and 5%, respectively) and headache (3 and 5%, respectively). Results from clinical trials suggest that lebrikizumab may be a viable alternative for AD management.
Publisher or Conference
Prajapati S, Fardos M, Desai AD, Feldman SR. The role of lebrikizumab in the treatment of atopic dermatitis in the adult population [published online ahead of print, 2023 Jul 4]. Immunotherapy. 2023;10.2217/imt-2023-0066. doi:10.2217/imt-2023-0066